These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16447792)

  • 1. [Clinical characteristics and pharmacotherapy of extremely disruptive behavior disorders in people with mental retardation].
    Tanaka K; Aita C; Hirano M
    No To Hattatsu; 2006 Jan; 38(1):19-24. PubMed ID: 16447792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
    Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes.
    Spreat S; Conroy J
    Psychiatr Serv; 1998 Apr; 49(4):510-2. PubMed ID: 9550242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature.
    Hässler F; Reis O
    Dev Disabil Res Rev; 2010; 16(3):265-72. PubMed ID: 20981765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later.
    Janowsky DS; Barnhill LJ; Khalid AS; Davis JM
    J Clin Psychiatry; 2006 Aug; 67(8):1272-7. PubMed ID: 16965207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG; Gharabawi GM;
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods.
    Luby JL; Stalets MM; Belden AC
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):205-15. PubMed ID: 17489715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Behavioral disorders and substance abuse in adolescents with mental retardation].
    Papachristou E; Anagnostopoulos D
    Psychiatriki; 2014; 25(2):139-50. PubMed ID: 25035183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychotropic medication use in children and adolescents in an inpatient setting.
    Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V
    Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems.
    Stolker JJ; Koedoot PJ; Heerdink ER; Leufkens HG; Nolen WA
    Pharmacopsychiatry; 2002 Jan; 35(1):19-23. PubMed ID: 11819154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychotropic medicines to patients with mental retardation].
    Bygdnes AM; Kristiansen A
    Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1028-30. PubMed ID: 17457386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability--a case series.
    Drmić S; Franić T
    Coll Antropol; 2008 Jun; 32(2):325-30. PubMed ID: 18756876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation.
    de Bildt A; Mulder EJ; Scheers T; Minderaa RB; Tobi H
    Pediatrics; 2006 Dec; 118(6):e1860-6. PubMed ID: 17142506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of behavioral problems in intellectually disabled adult patients with epilepsy.
    Kerr M; Gil-Nagel A; Glynn M; Mula M; Thompson R; Zuberi SM
    Epilepsia; 2013 Mar; 54 Suppl 1():34-40. PubMed ID: 23458464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.
    Scheifes A; de Jong D; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2013 Oct; 34(10):3159-67. PubMed ID: 23886758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopharmacoepidemiology of mental retardation: 1966 to 1995.
    Singh NN; Ellis CR; Wechsler H
    J Child Adolesc Psychopharmacol; 1997; 7(4):255-66. PubMed ID: 9542696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders.
    Stolker JJ; Heerdink ER; Leufkens HG; Clerkx MG; Nolen WA
    Gen Hosp Psychiatry; 2001; 23(6):345-9. PubMed ID: 11738466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms, treatment, and medication reactions for disruptive behavior disorders.
    Finks K
    NASN Sch Nurse; 2012 May; 27(3):125-8. PubMed ID: 22712112
    [No Abstract]   [Full Text] [Related]  

  • 20. [Deaths in a Tunisian psychiatric hospital: an eleven-year retrospective study].
    Zgueb Y; Jomli R; Ouertani A; Hechmi S; Ouanes S; Nacef F; Banaser A
    Encephale; 2014 Oct; 40(5):416-22. PubMed ID: 25132014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.